Open | - |
Close | - |
Volume / Avg. | 4.000 / 15.514K |
Day Range | - - - |
52 Wk Range | 0.181 - 19.497 |
Market Cap | $6.089M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 0.25% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of GT Biopharma (NASDAQ: GTBP) through any online brokerage.
Other companies in GT Biopharma’s space includes: Alzamend Neuro (NASDAQ:ALZN), Tharimmune (NASDAQ:THAR), Virios Therapeutics (NASDAQ:VIRI), Geovax Labs (NASDAQ:GOVX) and NexImmune (NASDAQ:NEXI).
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on Tuesday, August 8, 2023. The analyst firm set a price target for 5.00 expecting GTBP to rise to within 12 months (a possible 13.38% upside). 7 analyst firms have reported ratings in the last year.
The stock price for GT Biopharma (NASDAQ: GTBP) is $4.41 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for GT Biopharma.
GT Biopharma’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for GT Biopharma.
GT Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.